{
    "symbol": "CDXS",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 08:00:05",
    "content": " During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2022 revenues, product revenues and gross margin on product revenues, prospects for our Life Sciences Tools, food sector and Biotherapeutics product businesses and our expectations regarding the sales of one of our proprietary enzymes to Pfizer for the manufacture of their COVID-19 antiviral therapeutic, PAXLOVID. In life science tools, we are focused on driving increased adoption and product sales for our three commercial enzymes, advancing and adding to our R&D partnerships and building long-term value from our synergistic inorganic investments with Molecular Assemblies and seqWell. Please proceed with your questions. Please proceed with your questions. Please proceed with your questions. Please proceed with your questions."
}